Country Overviews: market research reports

... for pharmaceutical consumptiongrowth, which should also benefit from an expansion of private healthcare that is of increasing appeal tothe country’s growing middle class. However, we caution that cost-containment pressures are likely toprioritise generic and locally ...  |  read more...

... reduce unnecessary use of medicines. For example, the Bureauof National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tighteningits oversight of prescription drug distribution. Therefore, we envisage that main drivers ...  |  read more...

... is limited by its small market size and the increasingopenness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong. Headline Expenditure Projections Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 ...  |  read more...

... thecountry's economy. The Croatian pharmaceutical market continues to pose a challenging environment todomestic and international drugmakers, but we believe EU accession will ease the regulatory burden aslegislation is harmonised with EU norms. In 2013 the ...  |  read more...

... information and an analysis on the healthcare, regulatory and reimbursement landscape of France. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure ...  |  read more...

... looking to expand in the country. Meanwhile, domestic firms willcontinue to expand overseas (especially in emerging markets) in order to maintain revenue growth. Headline Expenditure Projections Pharmaceuticals: JPY10,358bn (US$129.7) in 2012 to JPY10,823bn (US$118.9bn) in ...  |  read more...

... information and analysis on Italy’s healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and the country’s healthcare infrastructure. Most ...  |  read more...

... will stand tobenefit from the patented to generic drug switch. However, given that generic costs is higher in Australia ascompared to other developed countries, a downside risk to the view is the lack of generic ...  |  read more...

... (US$268mn) in 2012 to NAD2.36bn (US$259mn) in 2013; +7.1% inlocal currency and -3.3% in US dollar terms. Healthcare: NAD5.08bn (US$619mn) in 2012 to NAD5.40bn (US$594mn) in 2013; +6.3% in localcurrency and -4.0% in US dollar ...  |  read more...

... significant health burden over the next twodecades. This will continue to limit revenue-earning opportunities for companies whose product portfolioscontain treatments for long-term diseases. Headline Expenditure Forecasts Pharmaceuticals: XAF67.65bn (US$136mn) in 2012 to XAF72.45bn (US$148mn) in ...  |  read more...

... market. It will also help to bring local drugmakers upto international standards, and in the long term, improve their competitiveness in the domestic and regionalmarkets. Foreign drugmakers with products which have been held to tougher ...  |  read more...

... improvements in various areas such as its healthcare deliveryservices, population's affluence and general improvements to its living standards before the country can seemajor investments from foreign pharmaceutical firms. Headline Expenditure Projections: Pharmaceuticals: BWP1.50bn (US$200mn) in ...  |  read more...

... facilities. Major US companies include Ascension Health, Fresenius, HCA, Kaiser Permanente, and Tenet Healthcare. Worldwide, health care expenditures total about $5 trillion annually, according to Swiss Re. Total health spending (both public and private) as ...  |  read more...